APTO-253 is able to induce DNA damage in AML cells and can exploit BRCA1/2 recombination deficiency July 16, 2018
Jiangsu Wanbang Biopharmaceutical cleared to begin clinical trials of SGLT2 inhibitor in China July 13, 2018
RSS